Disability-adjusted life years in the assessment of health effects of traffic-related air pollution.

Traffic-related air pollutants have an impact on human health and have been recognized as one of the main stressors that cause mortality and morbidity in urban areas. Research confirms that citizens living in the vicinity of main roads are strongly exposed to high concentrations of numerous air pollutants. In the present study the measurements of traffic-related parameters such as density, velocity, and structure were performed for cross-sections of selected street canyons in Warsaw, the capital city of Poland. In addition, the results of the general traffic measurements were used to describe the number of cars crossing the border of the city. Vehicle emissions of PM10 were calculated for the whole city area and changes of the PM10 concentration were modeled to present the exposure to this pollutant that could be attributable to traffic. The principles of the environmental burden of disease (EBD) were used. The assessment of the impact of traffic-related air pollutants on human health was made. The results, presented in disability-adjusted life years (DALY), were based on the outcomes of the study conducted in 2008-2012 in Warsaw, one the most congested agglomerations in Europe, and included the health damage effect of the exposure to high concentrations of air pollutants. DALY calculations were performed in accordance to the methodologies used in renowned international scientific research on EBD.

An open-label study of the treatment efficacy of olanzapine for Tourette's disorder.

BACKGROUND: An open-label trial was performed to explore efficacy and safety of olanzapine, an atypical neuroleptic with diverse receptor activity including both dopamine-2 and serotonin-2A and -2C antagonism, for treatment of Tourette's disorder. METHOD: Ten adult patients aged 20 to 44 years with Tourette's disorder were treated using an open-label, flexible dosing schedule for 8 weeks. Three patients who continued olanzapine were reevaluated after 6 months. Three subjects were psychotropic medication naive, 5 patients experienced intolerable side effects with conventional neuroleptics, and 2 patients had remote (> or = 10 years) successful response to conventional neuroleptics. Tic severity was rated by the Yale Global Tic Severity Scale; weight, vital signs, and adverse effects were assessed weekly. Electrocardiogram, laboratory studies, and comorbid symptoms, assessed by the Yale-Brown Obsessive Compulsive Scale and ADHD Behavior Checklist for Adults, were measured at baseline and at week 8. RESULTS: Two of 10 patients prematurely discontinued olanzapine owing to excessive sedation. Of 8 patients who completed the 8-week trial, 4 (50%) demonstrated reduction of global tic severity scores by > or = 20 points, and 6 (75%) demonstrated reductions by > or = 10 points. No significant changes in comorbid symptoms were demonstrated. Sedation, weight gain, increased appetite, dry mouth, and transient asymptomatic hypoglycemia were the most common side effects. Tic improvements were maintained in 3 patients reassessed 6 months later. Final olanzapine dosages ranged from 2.5 mg to 20 mg daily (mean = 10.9 mg/day). CONCLUSION: This open-label study suggests that olanzapine should be explored as a potential alternative to conventional neuroleptic medications for treatment of motor tics and Tourette's disorder.